- BeiGene’s revenue for Q1 exceeded estimates, generating $751.7 million which is a 68% increase year on year.
- Product revenue was also above the prediction at $746.9 million, increasing by a substantial 82% year on year.
- However, collaboration revenue underperformed, realised at $4.73 million against an estimated $9.33 million.
- The company saw a healthy gross margin of 83%.
- Whilst R&D expenses were lower than anticipated at $460.6 million, up just 13% year on year, against an estimate of $467.4 million.
- SG&A expense came in over the estimate at $427.4 million, against the $410.1 million estimate.
- Loss per share has improved year on year, with a loss of 19 cents per share this year compared to last year’s loss of 26 cents per share.
- Cash, cash equivalents, restricted cash and short-term investments amounted to $2.81 billion, unfortunately a decrease of 27% year on year.
- Notably, there were 19 buys and 2 holds, with 0 sales.
A look at BeiGene Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
BeiGene, a commercial stage biopharmaceutical company, is positioned positively for long-term growth according to Smartkarma Smart Scores. With a strong growth score of 4 and top marks in resilience with a score of 5, BeiGene appears well-equipped to thrive in the biopharmaceutical industry. The company’s focus on the discovery, development, and commercialization of cancer treatment drugs aligns with market demand, contributing to its high resilience score.
While BeiGene may not offer significant dividends currently, its overall outlook remains promising with momentum and value scores that indicate stability and potential for future value appreciation. The company’s commitment to advancing molecularly targeted and immuno-oncology treatments positions it as a key player in the global effort to combat cancer and improve patient outcomes.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
